On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19.
GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.
Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.
The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.
Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
The Biologics market has changed dramatically since the introduction of the Biologics Price Competition and Innovation Act in 2014 in the US. The act provides a pathway for similar biologics to make it to market safely, cost-effectively, and legally.
Chinese genome sequencing company BGI has been given the go-ahead to appeal an English High Court ruling in an ongoing lawsuit launched by competitor Illumina regarding its DNA sequencing patents.
Since the formalisation of the new Biologics Price Competition and Innovation Act framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.